Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: a single center experience

Eren O. O., Artac M., Boruban M. C., Yavas O., Arslan U., Basaranoglu M.

MEDICAL ONCOLOGY, vol.26, no.4, pp.386-392, 2009 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 4
  • Publication Date: 2009
  • Doi Number: 10.1007/s12032-008-9133-4
  • Journal Name: MEDICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.386-392
  • Keywords: Hepatitis B, Cytotoxic chemotherapy, Reactivation, Cancer, Lamivudine, CYTOTOXIC CHEMOTHERAPY, HBV REACTIVATION, PREEMPTIVE USE, RISK-FACTORS, LAMIVUDINE, CARRIERS, THERAPY, MALIGNANCIES, PREVENTION, INFECTION
  • Bezmialem Vakıf University Affiliated: No

Abstract

Hepatitis B reactivation due to chemotherapy is a cause of serious morbidity and mortality in some of the patients with cancer. In this study, we retrospectively assessed the prevalence of hepatitis B reactivation among the patients undergoing cytotoxic chemotherapy. We investigated efficacy of lamivudine prophylaxis against hepatitis B reactivation as well.